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The fifth Diagnostic and Statistical Manual of Mental Disorders (DSM-5) of the American 
Psychiatric Association [1] gives the following classifications of sexual dysfunctions: delayed 
ejaculation, erectile disorder, female orgasmic disorder, female sexual interest/arousal disor-
der, genito-pelvic pain/penetration disorder, male hypoactive sexual desire disorder, prema-
ture (early) ejaculation, substance-/medication-induced sexual dysfunction, other specified 
sexual dysfunction, and unspecified sexual dysfunction. It is evident that sexual dysfunctions 
constitute a heterogeneous group of disorders. They are characterized by clinically significant 
disturbances to respond sexually or experience sexual pleasure. Determining the character of 
the sexual dysfunction is a complex issue, which needs extensive clinical and psychological/
psychiatric expertise in order to come to a correct clinical judgment and includes partner and 
relationship factors, individual vulnerability, psychiatric comorbidity, stressors, and cultural, 
religious, and medical factors.
Sexual functioning involves a complex interaction of biological, sociocultural, and psychological 
factors, which makes a clear diagnosis sometimes rather difficult. In any case, problems should 
be ruled out that are caused by interfering factors, like drugs, medicines, a medical condition 
(e.g., pelvic nerve damage) or external factors like partner violence, or other severe stressors.
In the present volume, four chapters are included that represent various aspects involved in 
sexual behavior and its dysfunctions in a very broad sense. These chapters also give a window 
on the complex issues involved in normal and dysfunctional sexual interactions.
In Chapter 2, the focus is on erectile disorder or erectile dysfunction. Erectile dysfunction (ED) 
is defined as a disorder that is characterized by the incapacity to sufficiently achieve and main-
tain an erection in order to enjoy a satisfactory sexual relationship. After premature ejaculation, 
it is the most frequent sexual dysfunction in men. Erectile disorder is frequently, but not always, 
associated with cardiovascular risk factors, and the authors describe and discuss an elegant 
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study in Spain, using a very extensive tool of methods and measures on a large cohort of males. 
The results indicate a high prevalence of erectile dysfunction in patients with high vascular 
risks. Improvement in erectile dysfunction was clearly associated with improved control of 
these cardiovascular risk factors. The study nicely illustrates the complexities involved in erec-
tile problems and also in the difficulties in treating them properly. Moreover, the authors dis-
cuss the various factors that influence erectile functions like aging, lifestyle (smoking, diet), high 
blood pressure, atherosclerosis, and blood pressure medications. Although modifying lifestyle 
risk factors may help, in many cases patients also need medications to improve or correct erec-
tile problems [2]. Phosphodiesterase type 5 inhibitors (PDE5i) have revolutionized ED treat-
ment, although there are limitations in their use (e.g., diabetes and nerve injury patients often 
respond poorly to PDE5i). In the last decade, several new treatment strategies for the treatment 
of ED have been pursued, aiming at treating underlying microvascular abnormalities, restoring 
smooth muscle contractility, preventing cavernosal fibrosis, promoting endothelial revascular-
ization, modulating neurohumoral pathways, and regenerating new penile tissue [3].
Hypogonadism is the decrease or absence of hormonal secretion from the gonads. In males, 
this condition is called androgen deficiency and is characterized by a decrease or absence of 
testosterone (T) secretion from the testes. T plays an essential role in normal male development 
starting from the very early stage in life (intrauterine) and is necessary for the emergence and 
maintenance of many male characteristics and functions, including body mass, bone density, 
libido, potency, and spermatogenesis. It is also indispensable for normal sexual functioning 
in adult life, and in puberty T is extremely important for a mature male phenotype at somatic 
and genital areas in the body. In Chapter 3, by Stolan and coworkers, an extensive overview is 
given on the role of T levels in normal sexual life and the dramatic effects of the consequences 
of hypogonadism, i.e., low T levels. Not only classical hypogonadic types, due to testicular 
disease or caused by central nervous system-, hypothalamic-, or hypophyseal-induced hypo-
gonadism are described, but also the important partial T deficiency coinciding with aging 
is discussed. Apart from those, not only secondary T deficiency may occur due to problems 
associated with enhanced body weight (frequently seen in diabetes and metabolic syndrome) 
but also hypogonadism due to the chronic use of anabolic steroids or after long and intense 
stress exposure, even in young men. The authors describe therapeutic approaches to each 
kind of hypogonadism, based on individualized treatment including lifestyle changes, weight 
loss, exercising, and supplemental therapy. Because normal testosterone levels play a decisive 
role in various aspects of daily sex life, like daily sexual day dreaming or sexual fantasies, it 
is extremely evident how important normal T levels are for male sexual well-being. It can be 
easily seen that hypogonadism may lead to various complaints in daily life and in particular 
sexual complaints.
Mood disorders, and in particular major depression, are very often associated with sexual 
dysfunctions, both in male and in female patients. Such sexual dysfunctions cover the whole 
domain of sexual problems including libido, delayed ejaculations, erectile, and orgasmic dis-
turbances. When major depression needs urgent treatment with an antidepressant, the latter 
often (and particularly with serotonergic antidepressants like selective serotonin reuptake 
inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs)) comes 
with additional sexual side effects. This makes the situation for the patient often unbearable 
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and frequently leads to ceasing the treatment. In Chapter 4 (Olivier and coworkers), the vari-
ous factors that are involved in the complex interaction between the primary disorder (major 
depression) and the unwanted sexual dysfunctions (both caused by the disease itself and by 
the sexual side effects of the antidepressant) are described, primarily focused on men (mainly 
because the female domain is less well investigated). It appears extremely difficult to disen-
tangle the intrinsic sexual problems associated with depression from those induced by the 
antidepressant. Sexual dysfunctions remain one of the important reasons to noncompliance 
to the drug treatment, even if the depressive mood is lifted and the patient feels better. One of 
the big challenges for research of new antidepressants is the design and development of such 
compounds without sexual side effects, although other side effects should also be avoided if 
possible. There is an ongoing heavy discussion on the therapeutic efficacy of antidepressants 
(and all other psychotropic agents) and their side effects [4]. This discussion and its implica-
tions make it very clear that we lack fundamental insight in the cause of psychiatric diseases 
(including depression) and that fundamental research into the mechanisms of action of “nor-
mal” functioning should lead to insight into pathological functioning. Only then, it might be 
possible to design and develop new psychotropic drugs, including antidepressants that are 
true “medicines” instead of drugs that merely treat “symptoms.” Fundamental research of 
the brain is often difficult to perform directly in man, and animal research can be of utmost 
importance, although always caution should be used in the translation from animal to man 
because of sometimes large species differences. Chapter 4 also describes such an approach for 
sexual side effects of (novel) antidepressants. Because sexual side effects of antidepressants, 
at least in men, are relatively well described in the literature [5], those antidepressants can 
be used in a translational animal model that is sensitive to sexual side effects. The rat model 
reflects several aspects of the sexual side effects of classical antidepressants (tricyclics, SSRIs, 
SNRIs, NRIs), including delayed onset of action and disappearing of the sexual side effects 
after stopping treatment. Two recently introduced antidepressants vilazodone and vortiox-
etine, according to clinical studies [6, 7], exert no or less sexual side effects in depressed 
patients compared to classic antidepressants, especially the SSRIs. These two compounds had 
no sexual side effects in the rat model of sexual behavior used in Chapter 4. The model has 
considerable translational validity and can and will be used for future studies into sexual 
side effects of new antidepressants. Moreover, the model can also be used for fundamental 
research into the brain mechanisms and circuitry underlying sexual behavior. Understanding 
the normal functioning and inducing perturbations in this circuitry might help in finding new 
ways to treat side effects of novel and “real” psychotropic medicines.
A topic not dealt with in the present contributions but related to the use of antidepressants and 
the sexual inhibitory effects of the latter (notably the SSRIs) is premature ejaculation, one of 
the sexual dysfunctions mentioned in DSM-5. Premature ejaculation (PE) has been defined as 
persistent or recurrent ejaculation occurring during partnered sexual activity within approx. 1 
minute following vaginal penetration and before the person wishes it. PE must be present for 
at least 6 months and must be present on practically all occasions of sexual activity and causes 
clinically significant distress in the individual. PE cannot be better explained by a nonsexual 
mental disorder or as a consequence of a severe relationship distress or other major stress-
ors and is not caused by the effects of a substance/medication or another medical condition. 
PE can be lifelong or acquired, generalized, or situational and may have mild ( intravaginal 
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ejaculation latency time (IELT) of 30–60 seconds), moderate (IELT of 15–30 seconds), or severe 
(IELT<15 seconds) effects. Treatment by selective serotonin reuptake inhibitors (SSRIs) has 
really led to a paradigm shift in the understanding and treatment of PE as all SSRIs exert 
ejaculation delaying effects in men with PE [8, 9]. Although the treatment of PE by SSRIs is 
“off-label,” it is the present therapy used for PE, notwithstanding the nonsexual side effects 
and the need to take the medication daily and permanently [10]. An ideal anti-PE medication 
would be “on demand,” that can be taken shortly (hours) before sexual activity. Although it 
still would come with side effects, it is assumed that many men may prefer the convenience 
of “on demand” dosing compared to daily and long-term dosing [11]. The search for an “on 
demand” treatment for PE has led to the development of dapoxetine, which has received 
approval for treatment of PE in many countries, although it has not been approved by the 
US Food and Drug Administration (FDA). Dapoxetine is a potent SSRI, and it is postulated 
that its rapid absorption and rapid appearance of peak plasma concentration combined with 
a relatively short half-life lead to an ideal pharmacokinetic profile for such an “on demand” 
profile. Dapoxetine has some minor “on demand” efficacy but clearly is not a breakthrough 
medicine in the treatment of PE [11]. Another SSRI, with a comparable profile as dapoxetine, 
DA-8031 is in development for PE, but efficacy data have not yet been elucidated [12, 13]. 
Several other approaches for treatment of PE are used or are in development, including local 
anesthetics (e.g., lidocaine) used as cream, gel, or spray, and are moderately effective in delay-
ing ejaculation [10]. Several other compounds with various mechanisms of action (tramadol, 
α
1
-adrenoceptor antagonists, oxytocin antagonists, modafinil, and botulin-A toxin) have been 
proposed in the treatment of PE but need extensive testing and will not reach the market soon.
Treatment of female sexual dysfunction lags behind the available male treatments (ED, PE, 
hypogonadism). Low sexual desire is the most common sexual complaint in women, and 
many females suffer from sexual dissatisfaction that often negatively interferes with quality 
of life. Initially, these sexual complaints were classified as hypoactive sexual desire disor-
der (HSDD) but have merged in DSM-5 with female sexual arousal disorder (FSAD) into 
the diagnosis of female sexual interest/arousal disorder (FSIAD). Most research up to now 
has been using HSDD as the most common sexual dysfunction disorder that affects many 
women all over the world. A recent study in the USA found that more than 7% of US women 
suffer from HSDD [14]. In 2012, the FDA approved flibanserin (Addyi™) for the treatment of 
premenstrual women with HSDD. Flibanserin is a 5-HT
1A
 receptor agonist and 5-HT2A recep-tor antagonist and has moderate pro-sexual activities [15]. Several other hormonal (testoster-
one) and pharmacological (buspirone, bupropion) drugs have been tested but have not led 
yet to approved pharmacotherapy for FSIAD. Currently, two drugs are under investigation 
for the treatment of FSIAD that combine a low dose of sublingual testosterone with either a 
PDE5i (sildenafil) or a partial 5-HT
1A
 receptor agonist (buspirone) [16]. Sublingual T is rap-
idly absorbed, induces a rapid peak in T, and is eliminated within 2–3 h [16]. However, T 
induces an increase in sexual motivation 3–6 h after administration (therapeutic window). 
Administration of either sildenafil or buspirone in such a way that their therapeutic win-
dow coincides with that induced by T leads to rather strong pro-sexual effects [16]. The (T + 
PDE5i) treatment (Lybrido) appears particularly active in women with HSDD/FSIAD due to a 
relatively insensitive system for sexual cues and the (T + buspirone) treatment (Lybridos) for 
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HSDD/FSIAD women due to dysfunctional activation of sexual inhibitory mechanisms [16]. 
In a small study in women with SSRI-induced sexual dysfunction, both drug combinations 
also showed promising results [17]. Further development of these promising drugs will take 
time, but at least it indicates the possibility to develop efficient and innovative pharmacother-
apy for for FSIAD. Another potential medicine for FSIAD might come from influencing a com-
pletely different mechanism of action by bremelanotide, an agonist of melanocortin 3 (MC
3
) 
and MC4 receptors. Preliminary data are promising, but again further development need to show clear pro-sexual activity [15]. The positive message from all these developments is that 
the lack of effective medications to treat female sexual dysfunctions seems to come to an end.
Finally, in the last chapter by Egloff, various aspects of circumcision are described and dis-
cussed in a broad context. Biomedical, psychosomatic, psychotherapeutic, cultural, religious, 
clinical, and pharmacological aspects of circumcision are portrayed. The function of the fore-
skin, e.g., hygiene or protection of the glans penis, in normal (sexual) life is discussed, as well 
as in a clinical setting. Whether circumcision influences sexual behavior or may lead to sexual 
dysfunction, or, in contrast, improves sexual dysfunctions, is a matter of debate but certainly 
needs more research. The beauty of this chapter is that it adds a lot of additional facts and 
thoughts about the complexity of human sexuality.
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